<DOC>
	<DOCNO>NCT01769209</DOCNO>
	<brief_summary>This phase II trial study well give bortezomib together combination chemotherapy work treat patient relapsed refractory acute lymphoblastic leukemia . Bortezomib may stop growth cancer cell block enzymes need cell growth .</brief_summary>
	<brief_title>Bortezomib Combination Chemotherapy Treating Patients With Relapsed Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate bortezomib combination chemotherapy backbone doxorubicin ( doxorubicin hydrochloride ) , vincristine ( vincristine sulfate ) , PEG-asparaginase ( pegaspargase ) , dexamethasone patient relapsed/refractory acute lymphoblastic leukemia . SECONDARY OBJECTIVES : I . Determine progression free survival . II . Estimate rate complete response ( CR ) CR incomplete platelet recovery ( CRp ) re-induction compare historical baseline . III . Estimate failure-free survival ( FFS ) survival percent 1 year compare historical baseline . IV . Assess safety tolerability study drug . V. Determine whether bortezomib induces reactive oxygen specie ( ROS ) circulate acute lymphoblastic leukemia ( ALL ) blast cell . OUTLINE : Patients receive bortezomib subcutaneously ( SC ) day 1 , 4 , 8 , 11 ; doxorubicin hydrochloride intravenously ( IV ) day 1 ; pegaspargase IV intramuscularly ( IM ) day 5 22 ; vincristine sulfate IV day 1 , 8 , 15 , 22 ; dexamethasone orally ( PO ) daily day 1-14 ; cytarabine intrathecally ( IT ) day 1 methotrexate intrathecally ( IT ) day 15 . Patients central nervous system disease receive intrathecal treatment per investigator 's discretion . After completion study treatment , patient follow every 3 month 2 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care Female subject : Are postmenopausal least 1 year screen visit , OR Are surgically sterile , OR If childbearing potential , agree practice 2 effective method contraception , time , time signing informed consent form 30 day last dose bortezomib , agree completely abstain heterosexual intercourse Male subject , even surgically sterilize ( i.e. , status post vasectomy ) : Agree practice effective barrier contraception entire study treatment period minimum 30 day last dose study drug , OR Agree completely abstain heterosexual intercourse â€¢ The patient relapse refractory B T cell acute lymphoblastic leukemia progress follow least one prior therapy . Ph+ patient eligible . Relapsed ALL define patient reappearance leukemia cell peripheral blood bone marrow appearance extramedullary disease complete remission . Refractory ALL define patient failure achieve complete remission induction therapy . Complete remission define &lt; 5 % leukemia cell bone marrow recovery peripheral blood count . Relapsed disease document bone marrow biopsy ( &gt; 5 % cell bone marrow ) flow cytometry peripheral blood biopsy extramedullary disease . Must receive least one ( 1 ) line prior systemic therapy may NOT include VELCADE ( bortezomib ) ; patient undergo autologous/allogeneic stem cell transplantation eligible Transplant eligible patient eligible Eastern Cooperative Oncology Group ( ECOG ) performance status 02 No poorly control intercurrent illness include , limited , ongoing active infection , poorly control diabetes , symptomatic congestive heart failure , psychiatric illness opinion investigator would limit compliance study requirement Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 x upper limit normal Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) unless elevation deem due leukemia infiltration . In patient , dose modification may require base standard guideline . Patients must adequate renal function define creatinine clearance &gt; = 30 ml/minute ( CockcroftGault ) Patient &gt; 1.5 x ULN total bilirubin Patient &gt; = grade 2 peripheral neuropathy Patient myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality ; prior study entry , electrocardiogram ( ECG ) abnormality screen must document investigator medically relevant Patient hypersensitivity bortezomib , boron , mannitol Female subject pregnant lactate Serious medical psychiatric illness likely interfere participation clinical study Diagnosed treat another malignancy within 2 year enrollment , exception complete resection basal cell carcinoma squamous cell carcinoma skin , situ malignancy , lowrisk prostate cancer curative therapy Participation clinical trial investigational agent include trial throughout duration trial Radiation therapy within 3 week randomization ; enrollment subject require concurrent radiotherapy ( must localize field size ) defer radiotherapy complete 3 week elapse since last date therapy The patient expose &gt; = 350mg/m^2 anthracycline ( doxorubicin equivalent ) The patient leave ventricular ejection fraction &lt; 40 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>